Senti Biosciences shares are trading higher after the company reported a new strategic collaboration with Celest Therapeutics for the clinical development of SENTI-301A in China. Senti is eligible to receive up to $156 million in milestones and royalties.
Portfolio Pulse from Benzinga Newsdesk
Senti Biosciences has announced a strategic collaboration with Celest Therapeutics for the clinical development of SENTI-301A in China. Senti could receive up to $156 million in milestones and royalties.
November 06, 2023 | 10:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Senti Biosciences' new strategic collaboration with Celest Therapeutics could lead to up to $156 million in milestones and royalties.
The strategic collaboration with Celest Therapeutics for the clinical development of SENTI-301A in China could potentially bring significant financial benefits to Senti Biosciences, which could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100